肝细胞癌癌前异型增生结节的研究现状

焦俊喆; 李京涛; 闫曙光; 魏海梁; 鞠迪; 宋艺君; 常占杰

doi:10.3969/j.issn.1001-5256.2017.05.039

肝细胞癌癌前异型增生结节的研究现状

DOI: 10.3969/j.issn.1001-5256.2017.05.039

1. 陕西中医药大学
2. 陕西中医药大学附属医院

基金项目:

国家自然科学基金(81603612)；陕西省科技厅课题(2012SF2-11,2014K11-02-04-06,2016SF-234)；陕西省中医药管理局课题(15-JC009)；北京医学奖励基金会课题(YJHYXKYJJ-276)；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 2867
- HTML全文浏览量: 60
- PDF下载量: 530
- 被引次数: 0
出版历程
- 出版日期: 2017-05-20

Current research status of precancerous dysplastic nodules in hepatocellular carcinoma

Shaanxi University of Chinese Medicine, Xianyang

Research funding:

摘要

摘要:
异型增生结节(DN)是肝细胞癌(HCC)癌前病变向HCC演变的重要阶段,具有极高的癌变风险。依据细胞异型性的不同,DN可分为低度异型增生结节(LGDN)和高度异型增生结节(HGDN),总结了LGDN与HGDN的病理特点、影像学特征及生物标志物,简述了DN恶变为HCC的风险大小,指出应当提高临床医师对于HCC癌前病变DN的认识,通过对DN的筛查发现恶变风险高的结节并进行干预,以防止HCC的发生。
- 癌,肝细胞 /
- 异型增生结节 /
- 病理状态,体征和症状 /
- 生物学标记 /
- 综述
Abstract:
Dysplastic nodule (DN) is an important stage for precancerous hepatocellular carcinoma (HCC) lesions progressing to HCC and has a very high risk of canceration.According to the difference in atypia, DN is classified into low-grade DN (LGDN) and high-grade DN (HGDN) .This article summarizes the pathological features, radiological features, and biomarkers of LGDN and HGDN, briefly describes the risk of the canceration of DN into HCC, and points out that it is necessary to enhance the knowledge of DN, the precancerous HCC lesions, in clinical physicians.DN screening to identify nodules with a high risk of canceration and related intervention help to prevent the development of HCC.
- carcinoma, hepatocellular /
- dysplastic nodule /
- pathological conditions, signs and symptoms /
- biological markers /
- review

HTML全文

参考文献(39)

[1]GOMMA AI, KHAN SA, TOLEDANO MB, et al.Hepatocellularcarcinoma:epidemiology, risk factors and pathogenesis[J].World Gastroenterol, 2008, 14 (27) :4300-4308.

[2]YANG JD, KIM WR, COELHO R, et al.Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma[J].Clin Gastroenterol Hepatol, 2011, 9 (1) :64-70.

[3]KEW MC.The role of cirrhosis in the etiology of hepatocellular carcinoma[J].J Gastrointest Cancer, 2014, 45 (1) :12-21.

[4]LI Y, ZHANG Z, SHI J, et al.Risk factors for naturally-occurring early-onset hepatocellular carcinoma in patients with HBVassociated liver cirrhosis in China[J].Int J Clin Exp Med, 2015, 8 (1) :1205-1212.

[5]DI TL, SANGIOVANNI A, BORZIO M, et al.Advanced precancerous lesions in the liver[J].Best Pract Res Clin Gastroenterol, 2013, 27 (2) :269-284.

[6]HE LL, ZHAO YL, DU LL, et al.Reserch advances in pathological and imaging manifestations of hepatic nodular lesions[J].J Clin Hepatol, 2015, 31 (9) :1547-1550. (in Chinese) 何玲玲, 赵亚林, 杜林林, 等.肝结节性病变的病理和影像学表现[J].临床肝胆病杂志, 2015, 31 (9) :1547-1550.

[7]Chinese Society of Liver Cancer, Chinese Anti-Cancer Association;Liver Cancer Study Group, Chinese Society of Hepatology, Chinese Medical Association;Chinese Society of Pathology, Chinese Anti-Cancer Association, et al.Evidence-based practice guidelines for the standardized pathological diagnosis of primary liver cancer in China (2015 update) [J].J Clin Hepatol, 2015, 31 (6) :833-839. (in Chinese) 中国抗癌协会肝癌专业委员会, 中华医学会肝病会分会肝癌学组, 中国抗癌协会病理专业委员会, 等.原发性肝癌规范化病理诊断指南 (2015年版) [J].临床肝胆病杂志, 2015, 31 (6) :833-839.

[8]WANLESS IR.Terminology of nodular hepatocellular lesions[J].Hepatology, 1995, 22 (3) :983-993.

[9]The International Consensus Group for Hepatocellular Neoplasia.Pathologic diagnosis of early hepatocellular carcinoma:a report of the international consensus group for hepatocellular neoplasia[J].Hepatology, 2009, 49 (2) :658-664.

[10]PARK YN.Update on precursor and early lesions of hepatocellular carcinomas[J].Arch Pathol Lab Med, 2011, 135 (6) :704-715.

[11]NIU ZS, NIU XJ, WANG WH, et al.Latest developments in precancerous lesions of hepatocellular carcinoma[J].World J Gastroenterol, 2016, 22 (12) :3305-3314.

[12]SCHLAGETER M, TERRACCIANO LM, D'ANGELO S, et al.Histopathology of hepatocellular carcinoma[M]//Multidisciplinary treatment of hepatocellular carcinoma.Springer, 2013:7-10.

[13]WONG CM, YAM JW, NG IO.Molecular Pathogenesis of Hepatocellular Carcinoma[M]//Molecular Genetics of Liver Neoplasia.New York:Springer, 2010:160-174.

[14]KOBAYASHI M, IKEDA K, HOSAKA T, et al.Dysplastic nodules frequently develop into hepatocellular carcinoma in patients with chronic viral hepatitis and cirrhosis[J].Cancer, 2006, 106 (3) :636-647.

[15]IAVARONE M, MANINI MA, SANGIOVANNI A, et al.Contrast-enhanced computed tomography and ultrasound-guided liver biopsy to diagnose dysplastic liver nodules in cirrhosis[J].Dig Liver Dis, 2013, 45 (1) :43-49.

[16]OH BK, KIM YJ, PARK YN, et al.Quantitative assessment of h TERT mRNA expression in dysplastic nodules of HBV-related hepatocarcinogenesis[J].Am J Gastroenterol, 2006, 101 (4) :831-838.

[17]NG CH, CHAN SW, LEE WK, et al.Hepatocarcinogenesis of regenerative and dysplastic nodules in Chinese patients[J].Hong Kong Med J, 2011, 17 (1) :11-19.

[18]KIM TK, JANG HJ.Contrast-enhanced ultrasound in the diagnosis of nodules in liver cirrhosis[J].World J Gastroenterol, 2014, 20 (13) :3590-3596.

[19]REN S, YE ZX, ZHU LM.Pathological and imaging features of multistep process of cirrhosis nodules[J].J Clin Hepatol, 2011, 27 (4) :425-428. (in Chinese) 任崧, 叶兆祥, 朱理珉.肝硬化结节多步癌变的病理及影像学表现[J].临床肝胆病杂志, 2011, 27 (4) :425-428.

[20]WU B, SONG B.Nodular lesions of cirrhotic liver:imaging manifestations with pathologic correlation[J].Chin J Bases Clin Gen Surg, 2003, 10 (3) :288-294. (in Chinese) 吴苾, 宋彬.肝硬变结节性病变的影像学和相关病理学表现[J].中国普外基础与临床杂志, 2003, 10 (3) :288-294.

[21]SCHRAML C, KAUFMANN S, REMPP H, et al.Imaging of HCC-Current State of the Art[J].Diagnostics, 2015, 5 (4) :513-545.

[22]JIANG JY, LI XS, MA KS.Application of hepatobiliary-specific MRI contrast agent Gd-EOB-DTPA in preoperative evaluation of hepatobiliary patients[J].J Clin Hepatol, 2015, 31 (6) :996-998. (in Chinese) 蒋家云, 李雪松, 马宽生.钆塞酸二钠在肝胆手术术前评估中的应用[J].临床肝胆病杂志, 2015, 31 (6) :996-998.

[23]PATEL D, KELL A, SIMARD B, et al.The cell labeling efficacy, cytotoxicity and relaxivity of copper-activated MRI/PET imaging contrast agents[J].Biomaterials, 2011, 32 (4) :1167-1176.

[24]YOON KT, KIM JK, Ki IMDY, et al.Role of 18F-fluorodeoxyglucose positron emission tomography in detecting extrahepatic metastasis in pretreatment staging of hepatocellular carcinoma[J].Oncology, 2007, 72 (Suppl 1) :104-110.

[25]KUHN FP, CROOK DW, MADER CE, et al.Discrimination and anatomical mapping of PET-positive lesions:comparison of CT attenuation-corrected PET images with coregistered MR and CT images in the abdomen[J].Eur J Nucl Med Mol Imaging, 2013, 40 (1) :44-51.

[26]GONG L, WEI LX, REN P, et al.Dysplastic nodules with glypican-3 positive immunostaining:a risk for early hepatocellular carcinoma[J].PLo S One, 2014, 9 (1) :e87120.

[27]FU SJ, QI CY, XIAO WK, et al.Glypican-3 is a potential prognostic biomarker for hepatocellular carcinoma after curative resection[J].Surgery, 2013, 154 (3) :536-544.

[28]DI TL, FRANCHI G, PARK YN, et al.Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis[J].Hepatology, 2007, 45 (3) :725-734.

[29]DU JL, WEI LX, WANG YL.Expression and clinicopathologic significance of GPC3 and other antibodies in well-differentiated hepatocellular carcinoma[J].Chin J Pathol, 2011, 40 (1) :11-16. (in Chinese) 杜经丽, 韦立新, 王玉兰.磷脂酰肌醇蛋白聚糖3等抗体在高分化肝细胞肝癌中的表达及其鉴别诊断意义[J].中华病理学杂志, 2011, 40 (1) :11-16.

[30]KONDO F.Histological features of early hepatocellular carcinomas and their developmental process:for daily practical clinical application[J].Hepatol Int, 2009, 3 (1) :283-293.

[31]PARK YN, KOJIRO M, DI TL, et al.Ductular reaction is helpful in defining early stromal invasion, small hepatocellular carcinomas, and dysplastic nodules[J].Cancer, 2007, 109 (5) :915-923.

[32]JEGO G, HAZOUME A, SEIGNEURIC R, et al.Targeting heat shock proteins in cancer[J].Cancer Lett, 2010, 332 (2) :275-285.

[33]LI RK.Expressions of HSP90α, HSP70, HSP60 incolon cancer tissue and the relationship between the expressions of HSP90α, HSP70, HSP60 and the extent of tissue differentiation[J].J Clin Exp Med, 2015, 14 (9) :721-723. (in Chinese) 李如凯.结肠癌组织中的HSP90α、HSP70、HSP60表达及其与组织分化程度的关系[J].临床和实验医学杂志, 2015, 14 (9) :721-723.

[34]CHUMA M, SAKAMOTO M, YAMAZAKI K, et al.Expression profiling in multistage hepatocarcinogenesis:identification of HSP70as a molecular marker of early hepatocellular carcinoma[J].Hepatology, 2003, 37 (1) :198-207.

[35]KOEHNE de GONZALEZ AK, SALOMAO MA, LAGANA SM.Current concepts in the immunohistochemical evaluation of liver tumors[J].World J Hepatol, 2015, 7 (10) :1403-1411.

[36]LI L, WANG LN, HE BW, et al.Expression of CD34 in hepatocellular carcinoma and analysis of sinusoids[J].Shaanxi Med J, 2007, 36 (5) :577-579. (in Chinese) 李莉, 王莉娜, 贺伯伟, 等.CD34在肝癌发生过程中的表达及肝窦毛细血管化分析[J].陕西医学杂志, 2007, 36 (5) :577-579.

[37]YAO S, ZHANG J, CHEN H, et al.Diagnostic value of immunohistochemical staining of GP73, GPC3, DCP, CD34, CD31, and reticulin staining in hepatocellular carcinoma[J].J Histochem Cytochem, 2013, 61 (9) :639-648.

[38]PARKY N, CHAE KJ, KIM YB, et al.Apoptosis and proliferation in hepatocarcinogenesis related to cirrhosis[J].Cancer, 2001, 92 (11) :2733-2738.

[39]NIU ZS, NIU XJ, WANG M.Management of hepatocellular carcinoma:Predictive value of immunohistochemical markers for postoperative survival[J].World J Hepatol, 2015, 7 (1) :7-27.

施引文献

资源附件(0)

访问统计